Biodexa Pharmaceuticals Plc (BDRX) P/E Ratio History
Insufficient DataInsufficient historical P/E data to classify valuation. · Data 2026–2026
Loading P/E history...
P/E Ratio Analysis
As of June 23, 2026, Biodexa Pharmaceuticals Plc (BDRX) trades at a price-to-earnings ratio of -0.0x, with a stock price of $3.01 and trailing twelve-month earnings per share of $-53.57.
Compared to the Healthcare sector median P/E of 22.1x, BDRX trades at a 100% discount to its sector peers. The sector includes 233 companies with P/E ratios ranging from 0.0x to 194.5x.
Relative to the broader market, BDRX trades at a notable discount to the S&P 500 median P/E of 24.3x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our BDRX DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
BDRX Cross-Benchmark Valuation
How does the current P/E compare to sector peers and the broader market?
BDRX P/E vs Peers
Drug Delivery Technology Platforms peers sorted by market cap
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $311M | 13.1 | - | -60% | |
| $4B | 9.6 | - | +68% | |
| $2B | 6.9Lowest | 0.66 | +817%Best | |
| $9B | 97.2 | - | -33% | |
| $28B | 21.4 | 0.53Best | +5% |
Lower P/E can signal a discount or weaker growth expectations; PEG adds growth context.
Intrinsic Valuation
DCF models, multiple analysis, and analyst estimates.
Historical Returns
10-year return with dividends reinvested.
DCA Calculator
See how regular investing compounds over time.
Peer Comparison
Compare growth, multiples, and margins vs sector.
BDRX — Frequently Asked Questions
Quick answers to the most common questions about buying BDRX stock.
What is BDRX's P/E ratio?
Biodexa Pharmaceuticals Plc (BDRX) trailing twelve-month P/E ratio is -0.0x, based on TTM diluted EPS of $-53.57. The 5-year average P/E is N/A and the historical range spans N/A to N/A.
Is BDRX stock overvalued or undervalued?
BDRX current P/E: -0.0x. 5-year average P/E: N/A. Percentile: N/A.
Is BDRX stock expensive?
BDRX is fairly valued relative to its own history. The current P/E of -0.0x is near the 5-year average of N/A (N/A percentile of historical range).
What is BDRX's historical P/E range?
Over the past 5 years, BDRX's P/E ratio has ranged from N/A to N/A, with a median of N/A and an average of N/A. The current P/E of -0.0x places the stock at the N/A percentile of this range. Full historical data spans 2026–2026.
How does BDRX's P/E compare to the S&P 500?
BDRX current P/E: -0.0x. S&P 500 median P/E: 24.3x.
How does BDRX's valuation compare to Healthcare peers?
Biodexa Pharmaceuticals Plc P/E of -0.0x can be benchmarked against Healthcare peers in the comparison table on this page.
What is BDRX's PEG ratio?
BDRX PEG ratio is N/A, based on a P/E of -0.0x and EPS growth of 100.0%. PEG normalises P/E by growth and helps compare stocks with different earnings trajectories.
What is BDRX's earnings yield?
BDRX earnings yield is N/A, the inverse of its -0.0x P/E ratio. Earnings yield represents the percentage of each dollar invested that the company earns. It can be compared directly to bond yields to assess relative attractiveness of stocks versus fixed income.